{
    "2021-08-13": [
        [
            {
                "time": "2021-08-13",
                "original_text": "药明康德(603259)：CXO龙头 迭创新高",
                "features": {
                    "keywords": [
                        "药明康德",
                        "CXO",
                        "龙头",
                        "创新高"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-13",
                "original_text": "天风证券维持药明康德买入评级：2021H1业绩超预期，增长动力强劲",
                "features": {
                    "keywords": [
                        "天风证券",
                        "药明康德",
                        "买入评级",
                        "业绩超预期",
                        "增长动力强劲"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-13",
                "original_text": "药明康德上半年营收超百亿，近30亿营收来自全球20大制药企",
                "features": {
                    "keywords": [
                        "药明康德",
                        "营收超百亿",
                        "全球20大制药企"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-13",
                "original_text": "年内上市公司理财规模达7664亿 传统结构性存款和银行理财仍是主战场",
                "features": {
                    "keywords": [
                        "上市公司",
                        "理财规模",
                        "结构性存款",
                        "银行理财"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-08-13",
                "original_text": "光大证券：维持药明康德(603259.SH)“买入”评级 临床前CRO及CDMO业务持续高速发展",
                "features": {
                    "keywords": [
                        "光大证券",
                        "药明康德",
                        "买入评级",
                        "临床前CRO",
                        "CDMO",
                        "高速发展"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-13",
                "original_text": "招商证券：维持药明康德(603259.SH)“强烈推荐-A”评级 CDMO业务高速增长",
                "features": {
                    "keywords": [
                        "招商证券",
                        "药明康德",
                        "强烈推荐-A",
                        "CDMO",
                        "高速增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-13",
                "original_text": "国泰君安：维持药明康德(603259.SH)“增持”评级 目标价195元",
                "features": {
                    "keywords": [
                        "国泰君安",
                        "药明康德",
                        "增持评级",
                        "目标价195元"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-13",
                "original_text": "药明康德（603259）2021年中报点评：业绩超市场预期，合全药业CDMO业务驱动高增长",
                "features": {
                    "keywords": [
                        "药明康德",
                        "中报",
                        "业绩超预期",
                        "CDMO",
                        "高增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}